Jose Santiago Santa-Cruz Sanchez
Family Medicine · Grandview, WANPI 1972986818
Payments from drug & device makers
Across 148 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$749
- AbbVie$549
- Bayer$231
- Sunovion Pharmaceuticals Inc.$176
- Novo Nordisk$173
- Supernus Pharmaceuticals, Inc.$119
- plus $720 from 18 others
What the payments were for
- Food & beverage$2,711100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $749 |
| AbbVie(2 entities) | 26 | $549 |
| Bayer | 12 | $231 |
| Sunovion Pharmaceuticals Inc. | 15 | $176 |
| Novo Nordisk | 9 | $173 |
| Supernus Pharmaceuticals, Inc. | 14 | $119 |
| GSK | 5 | $96 |
| Lilly USA, LLC | 4 | $87 |
| Sanofi Pasteur Inc. | 5 | $81 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| Merck | 2 | $30 |
| Organon | 3 | $29 |
| Harmony Biosciences LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Amgen | 1 | $13 |
| Roche Diagnostics Corporation | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,717 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xigduo XrDapaglifloz Propaned/Metformin | 170 | $151,935 |
| FarxigaDapagliflozin Propanediol | 124 | $126,522 |
| OzempicSemaglutide | 78 | $116,335 |
| RybelsusSemaglutide | 69 | $97,748 |
| EliquisApixaban | 76 | $94,972 |
| KerendiaFinerenone | 85 | $80,949 |
| TrulicityDulaglutide | 58 | $77,782 |
| Bydureon BciseExenatide Microspheres | 38 | $51,228 |
| XifaxanRifaximin | 15 | $47,543 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 39 | $46,506 |
| EntrestoSacubitril/Valsartan | 40 | $40,412 |
| SynjardyEmpagliflozin/Metformin Hcl | 26 | $31,374 |
| JardianceEmpagliflozin | 16 | $26,002 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $21,002 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $19,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $173 | $214,083147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $749 | $146,109152 claims |
| PfizerEliquis | $14 | $94,97276 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $87 | $92,39772 claims |
| BayerKerendia | $231 | $80,94985 claims |
| GSKBreo Ellipta, Incruse Ellipta | $96 | $16,24031 claims |
| MerckJanuvia | $30 | $6,34311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Grandview
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.